Books > Science & Mathematics > Biology, life sciences > Biochemistry
|
Buy Now
Targeted Interference with Signal Transduction Events (Hardcover, 2007 ed.)
Loot Price: R2,972
Discovery Miles 29 720
|
|
Targeted Interference with Signal Transduction Events (Hardcover, 2007 ed.)
Series: Recent Results in Cancer Research, 172
Expected to ship within 10 - 15 working days
|
Two aspects of biological research are major contributors to the
progress in the understanding of cancer etiology and the
development of new and improved cancer drugs. The sequencing of the
human genome provides us with a basic overview of all our genes and
gene products, and the insights into signaling pathways allow us to
align crucial components of cellular regulation into an ordered
functional context. A comparison of the genes in normal and in
tumor cells shows that mutations in the DNA of a limited set of
genes are responsible for the multiple stages of tumorigenesis and
metastasis. Many of the affected genes, including oncogenes, tumor
suppressor genes and genome stability genes, can be fitted into
pathways. They encode molecules that stimulate tumor cell division
or inhibit their death. Matching of therapeutic intervention with
insights into the underlying molecular disease mechanism has
already led to the development of drugs such as Herceptin and
Glivec. The deregulation of pathways as a consequence of the
altered biochemical function of mutated cancer genes provides the
conceptual basis for future progress. Will it be possible to
extrapolate this principle and derive more efficient drugs
targeting cancer pathway components? Promising cell surface
molecules, potential targets of monoclonal antibodies, and
intracellular molecules with enzymatic activity, potential targets
for low-molecular-weight synthetic inhibitors, have been
identified. Our ability to predict the consequences of inhibition
of such components, however, is still limited. For this reason, the
development of targeted drugs remains a complex process, comprising
rational and empirical elements. The state of development of
tomorrow s cancer drugs, directed against growth factors, growth
factor receptors and intracellular signaling molecules with kinase
activities, is described in this book.
General
Imprint: |
Springer-Verlag
|
Country of origin: |
Germany |
Series: |
Recent Results in Cancer Research, 172 |
Release date: |
June 2007 |
First published: |
2007 |
Editors: |
B. Groner
|
Dimensions: |
244 x 170mm (L x W) |
Format: |
Hardcover
|
Pages: |
188 |
Edition: |
2007 ed. |
ISBN-13: |
978-3-540-31208-6 |
Categories: |
Books >
Science & Mathematics >
Biology, life sciences >
Biochemistry >
General
|
LSN: |
3-540-31208-0 |
Barcode: |
9783540312086 |
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.